press release-凯发88

english 凯发88-凯发vip-娱乐凯发app下载中文繁体

english 凯发88-凯发vip-娱乐凯发app下载中文繁体

news press release media report

year:

select

press release

26 november 2021

envafolimab, the world’s first subcutaneously injected pd-l1 antibody approved by nmpa! alphamab oncology partners with 3dmed and simcere to innovate immunotherapy envafolimab is the world's first and only subcutaneously injected pd- l1
24 november 2021

ind application for phase 3 registration study of kn046 in combination with chemotherapy for the treatment of pancreatic cancer was approved by cde we look forward to bringing new treatment options to address the urgent unmet clinical needs.
23 november 2021

results of kn046 combined with kn026 in the treatment of patients with metastatic her2-positive breast cancer will be presented in sabcs 2021 preliminary safety and efficacy results of kn046 in combination with kn026 in patients with metastatic her2-positive breast cancer
03 november 2021

alphamab oncology appoints mr. jing han as chief commercial officer mr. han will be responsible for the company's commercialization strategy and execution, and report to dr. ting xu, chairman & ceo of alphamab oncology.
03 november 2021

first patient dosed in clinical study of kn046 in combination with alk-1 antibody in advanced or refractory solid tumors to evaluate the safety, tolerability, pharmacokinetics (pk) and anti-tumor activity of kn046 in combination with alk-1 antibody in patients with advanced or refractory solid tumors, including hepatoce...
29 october 2021

alphamab oncology announces first patient dosed in the pivotal clinical study of kn046 for the treatment of pd-(l)1 refractory advanced nsclc to evaluate the efficacy of kn046 combined with lenvatinib versus docetaxel in patients with advanced nsclc who have progressed on anti-pd-(l)1 treatment.
21 october 2021

ind application for phase iii clinical study of anti-her2 bispecific antibody kn026 was officially accepted by cde will initiate a pivotal clinical study of kn026 combined with chemotherapy in advanced gastric and gastroesophageal junction cancer (gc/gej) patients who progressed after first-line standard chemother...
18 october 2021

alphamab oncology completed enrollment in the first pivotal phase iii clinical study of the bispecific antibody kn046 a first interim analysis is going to be performed in the first quarter of 2022.
28 september 2021

alphamab oncology and raygene pharmaceutical announced partnership to develop combination therapy of bispecific antibody kn046 and small molecule drug rg001 for the posterior line treatment of advanced hcc and liver metastasis crc.
27 september 2021

alphamab oncology updated the efficacy of a phase ii clinical study of kn046 combined with chemotherapy in the first-line treatment of pancreatic cancer at csco annual meeting the orr was 50.0%, and the dcr was 95.5%,the 6-month progression-free survival rate was 62.3%.